Tel: 732-484-9848
Fax: 888-484-5008
Email: [email protected]
Building blocks
Bioactive molecules
Product Pathways
All Targets
Antibody-drug conjugate....
Biochemical Reagent
Cell Cycle/DNA Damage
GPCR/G protein
JAK/STAT Signaling
MAPK/ERK Pathway
Membrane Transporter/Io....
Metabolic Enzyme/Protease
Neuronal Signaling
Protein Tyrosine Kinase....
Stem Cells/Wnt
Vitamin D Related
Research Area
Cardiovascular Disease
Metabolic Disease
Neurological Disease
Product Type
All Products
New Products
Featured Products
Home   »   Product Pathways  »    »  SNX-2112

Products are for research use only. Not for human use. We do not sell to patients.

CS-0481 SNX-2112

(SNX2112; SNX 2112)
Structure Price and Availability of    SNX-2112
United States
Size Price Stock
100mg Get quote Inquiry
10mg Get quote
5mg Get quote
50mg Get quote
100 mg Get quote
200 mg Get quote
 Distributor In Japan:  フナコシ株式会社    電話番号:81-3-5684-1620   
Inquiry for price and availability only. Please place your order via our email or fax.
Contact us for competitive discounts on bulk quantities .
  • Data Sheet
  • Introduction
  • References
  • Related Products

SNX-2112  M.Wt:  464.48
SNX-2112  Formula: C23H27F3N4O3
SNX-2112  Solubility: DMSO: 93 mg/mL, H2O: < 1 mg/mL
SNX-2112  Purity: >98%
SNX-2112  Storage:  Please store the product under the recommended conditions in the Certificate of Analysis.
CAS: 908112-43-6

View current batch:

SNX-2112 is a potent synthetic heat shock protein 90 (HSP90) inhibitor with an IC50 of 0.92 μM for K562 cells. IC50 Value: 0.92 μM for K562 cells Target: HSP90 in vitro: SNX-2112 competitively binds to the N-terminal adenosine triphosphate binding site of Hsp90. SNX-2112 induces apoptosis via caspase-8, -9, -3, and poly (ADPribose) polymerase cleavage. SNX-2112 inhibits cytokine-inducedAkt and extracellular signal-related kinase (ERK) activation and also overcomes the growth advantages conferred by interleukin-6, insulin-like growth factor-1, and bone marrow stromal cells. SNX-2112 inhibits tube formation by human umbilical vein endothelial cells via abrogation of eNOS/Akt pathway and markedly inhibits osteoclast formation via down-regulation of ERK/c-fos and PU.1. Cell lines (eight cell lines from osteosarcoma, neuroblastoma, hepatoblastoma, and ymphoma) studied demonstrates sensitivity to SNX-2112 with IC50 values ranging from 10-100 nM. A higher dose (70 nM) exhibits a more prolonged inhibition and larger sub-G1 accumulation. Observed levels of Akt1 and C-Raf are markedly reduced over time along with an increase in PARP cleavage. A recent research indicates NX-2112 induces autophagy in a time- and dose-dependent manner via Akt/mTOR/p70S6K inhibition. SNX-2112 induces significant apoptosis and utophagy in human melanoma A-375 cells, and may be an effective targeted therapy agent. in vivo: SNX-2112, delivered by its prodrug SNX-5422, inhibits MM cell growth and prolongs survival in a xenograft murine model and blockade of Hsp90 by SNX-2112 not only inhibits MM cell growth but also acts in the bone marrow microenvironment to block angiogenesis and osteoclastogenesis.

Keywords: buy SNX-2112 | SNX-2112 Supplier | purchase SNX-2112 | SNX-2112 cost | SNX-2112 manufacturer | order SNX-2112 | SNX-2112 distributor | SNX-2112 structure,chemscene
buy 908112-43-6 | 908112-43-6 Supplier | purchase 908112-43-6 | 908112-43-6 cost | 908112-43-6 manufacturer | order 908112-43-6 | 908112-43-6 distributor | 908112-43-6 structure,chemscene

Tel: 732-484-9848
Fax: 888-484-5008
Email:  [email protected]
Address: 11 Deer Park Drive, Suite 102D Monmouth Junction, NJ 08852.
Products are for research use only. Not for human use. We do not sell to patients. Sitemap | Inhibitor © Copyright 2012. All Rights Reserved.